The majority of acute COVID-19 patients (14 of 16, 88%) with a detectable ANA were in this weakly-reactive, indeterminate classification, and the two remaining patients with a strongly positive antinuclear antibodies had a known prior history of systemic lupus erythematosus and autoantibodies. The gene discussed is BTG3; the disease is COVID-19.